Bionor Holding As
Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x and Vacc-C5 in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor retains full ownership rights to the HIV immunotherapy Vacc-4x and Vacc-C5, i.e, the upside potential from partnering or licensing remains with the Company.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Bionor Holding As
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Bionor Holding As
5 distinct titles indexed · top 5 shown.
- 1cfo
- 1chief executive officer
- 1cmo
- 1contract database administrator
- 1evp
Sign up to unlock all 5 contacts at Bionor Holding As
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Bionor Holding As
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.